By blocking paracellular phosphate transport, tenapanor added to phosphate binders may improve the hyperphosphatemia management in patients on maintenance dialysis, a study found.
Adding aliskiren to losartan in patients with nondiabetic chronic kidney disease does not result in a greater renal protection and increases their risk of hyperkalemia, a study found.
Patients with CKD who discontinued ACE inhibitors or angiotensin receptor blockers after a hyperkalemia episode had a 2.6-fold increased risk of all-cause mortality compared with patients who continued taking the drugs.
Newly released safety data also show that roxadustat is associated with reduced cardiovascular risks compared with epoetin alfa.
In a study, approximately one-fifth of CKD patients with metabolic acidosis received a diagnostic code for it.
Hyperkalemia in patients with chronic kidney disease (CKD) stage 3 or 4 more than doubles their risk of progressing to CKD stage 5, a study found.
Gout that develops in kidney transplant recipients increases their risk of worse outcomes, according to 2 new studies.
In a study, two-thirds of hemodialysis patients met criteria for frailty, which impairs independence, cognition, mood, and quality of life.
Kidney disease patients who took magnesium-containing antacids were 15% more likely to experience hip fracture than nonusers of antacids.
In turn, individuals with post-dialysis hypertension have significantly greater risks for all-cause mortality.
In a study, hemodialysis patients with the highest and lowest FGF23 levels had higher risks for ESA hyporesponsiveness.
In a phase 3 trial, difelikefalin, a kappa opioid receptor agonist, significant decreased itching and improved itching-related quality of life among dialysis patients suffering from pruritus.
Adult patients who used angiotensin receptor blockers prior to surgery had significant 30% increased odds of acute kidney injury, an Icelandic study found.
In a study, spironolactone treatment was not significantly better than placebo in preventing diabetic nephropathy in patients with high-risk type 2 diabetes.
In a pooled analysis of data from 3 studies, patiromer lowered potassium levels into a target range of 3.8 to 5.0 mEq/L in 92.5% and 96.8% of patients with baseline potassium levels of 6.0 mEq/L or higher and less than 6.0 mEq/L, respectively.